Literature DB >> 16731674

A case of severe eczema following use of imiquimod 5% cream.

C L Taylor1, M Maslen, M Kapembwa.   

Abstract

Imiquimod 5% cream, an immune response modifier licensed for treatment of external ano-genital warts and superficial basal cell carcinomata, is known to cause local erythema, oedema and, rarely, exacerbation of psoriasis. We describe a case of exacerbation of eczema following application of this cream in a man with penile warts.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16731674      PMCID： PMC2564744          DOI： 10.1136/sti.2005.018226

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN： 1368-4973            Impact factor:   3.519


  2 in total

Review 1.  Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions.

Authors:  Daniel N Sauder
Journal:  J Cutan Med Surg       Date:  2004       Impact factor: 2.092

2.  Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%.

Authors:  I Arany; S K Tyring; M A Stanley; M A Tomai; R L Miller; M H Smith; D J McDermott; H B Slade
Journal:  Antiviral Res       Date:  1999-08       Impact factor: 5.970
  2 in total
  1 in total

Review 1.  Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.

Authors:  Antona J Wagstaff; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.